At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IDRA Idera Pharmaceuticals
Pre-Market Trading 11-26 05:41:01 EST
0.4250
+0.0000
0.00%
High0.4250
Low0.4250
Vol0.00
Open0.4250
D1 Closing0.4250
Amplitude0.00%
Mkt Cap1.56M
Tradable Cap1.08M
Total Shares3.67M
T/O172.68K
T/O Rate0.00%
Tradable Shares2.54M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
IDRA stock slips ahead of reverse stock split (NASDAQ:IDRA)
BRIEF-Idera Pharmaceuticals Inc Says By Decision Dated Jan 10, Nasdaq Panel Granted Co Extension Until Jan 20, To Complete Shareholder Meeting & Attendant Transactions
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.